116 related articles for article (PubMed ID: 30018024)
1. YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.
Gibbert L; Hermert D; Wang J; M Breitkopf D; Alidousty C; Neusser M; Cohen CD; Gröne E; Macheleidt I; Rauen T; Braun GS; Floege J; Ostendorf T; Raffetseder U
Clin Immunol; 2018 Sep; 194():67-74. PubMed ID: 30018024
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney.
Hanssen L; Frye BC; Ostendorf T; Alidousty C; Djudjaj S; Boor P; Rauen T; Floege J; Mertens PR; Raffetseder U
J Immunol; 2011 Jul; 187(1):298-308. PubMed ID: 21606250
[TBL] [Abstract][Full Text] [Related]
3. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
Singh L; Singh G; Sharma A; Sinha A; Bagga A; Dinda AK
Hum Pathol; 2015 Jan; 46(1):34-9. PubMed ID: 25449629
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
Pontrelli P; Rossini M; Infante B; Stallone G; Schena A; Loverre A; Ursi M; Verrienti R; Maiorano A; Zaza G; Ranieri E; Gesualdo L; Ditonno P; Bettocchi C; Schena FP; Grandaliano G
Transplantation; 2008 Jan; 85(1):125-34. PubMed ID: 18192922
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitors: a double-edged sword.
Ume AC; Wenegieme TY; Williams CR
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F336-F341. PubMed ID: 33225712
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
8. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis.
Wang J; Gibbert L; Djudjaj S; Alidousty C; Rauen T; Kunter U; Rembiak A; Enders D; Jankowski V; Braun GS; Floege J; Ostendorf T; Raffetseder U
Kidney Int; 2016 Dec; 90(6):1226-1237. PubMed ID: 27591085
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts.
Prókai Á; Csohány R; Sziksz E; Pap D; Balicza-Himer L; Boros S; Magda B; Vannay Á; Kis-Petik K; Fekete A; Peti-Peterdi J; Szabó AJ
Transplantation; 2016 Feb; 100(2):325-333. PubMed ID: 26502369
[TBL] [Abstract][Full Text] [Related]
12. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
Hesselink DA; Bouamar R; van Gelder T
Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
[TBL] [Abstract][Full Text] [Related]
13. CD44 as a pathological marker for the early detection of calcineurin inhibitor-induced nephrotoxicity post kidney transplantation.
Hayashi A; Okamoto T; Nio-Kobayashi J; Iwahara N; Suzuki R; Ueda Y; Takahashi T; Yasuyuki Sato ; Iwanaga T; Hotta K
Biomed Res; 2022; 43(5):181-186. PubMed ID: 36244796
[TBL] [Abstract][Full Text] [Related]
14. Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy.
Luo K; Lim SW; Quan Y; Cui S; Shin YJ; Ko EJ; Chung BH; Yang CW
Oxid Med Cell Longev; 2019; 2019():1825018. PubMed ID: 31772699
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of calcineurin/NFAT pathway plays an essential role in renoprotective effect of tropisetron in early stage of diabetic nephropathy.
Barzegar-Fallah A; Alimoradi H; Razmi A; Dehpour AR; Asgari M; Shafiei M
Eur J Pharmacol; 2015 Nov; 767():152-9. PubMed ID: 26481166
[TBL] [Abstract][Full Text] [Related]
16. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
17. Sequential extracellular matrix-focused and baited-global cluster analysis of serial transcriptomic profiles identifies candidate modulators of renal tubulointerstitial fibrosis in murine adriamycin-induced nephropathy.
Sadlier DM; Connolly SB; Kieran NE; Roxburgh S; Brazil DP; Kairaitis L; Wang Y; Harris DC; Doran P; Brady HR
J Biol Chem; 2004 Jul; 279(28):29670-80. PubMed ID: 15033991
[TBL] [Abstract][Full Text] [Related]
18. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitors and nephrotoxicity in children.
Liu F; Mao JH
World J Pediatr; 2018 Apr; 14(2):121-126. PubMed ID: 29532435
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
